Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
NCT03712904 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · PHASE2 · terminated · last registry update 2025-09-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VEGFA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-18Results posted on the registry: Regeneron Pharmaceuticals, Aflibercept 8 mg (NCT06491914)
- 2026-09-11Phase 3 first posted: Ollin Biosciences, Inc., OLN324 + Aflibercept (NCT07816315)
- 2026-09-11Phase 3 first posted: Ollin Biosciences, Inc., OLN324 + Ranibizumab (NCT07816289)
- 2026-08-03Results posted on the registry: Outlook Therapeutics, Inc., bevacizumab + ranibizumab (NCT03834753)
- 2026-08-03Results posted on the registry: Mylan Pharmaceuticals Inc, MYL-1701P, a proposed biosimilar to Eylea (NCT04674800)
- 2026-07-29Phase 3 first posted: Kodiak Sciences Inc, Tabirafusp tedromer + Aflibercept (2.0 mg) (NCT07734844)
- 2026-07-29Results posted on the registry: The Cleveland Clinic, Dexamethasone implant + Aflibercept (NCT04411693)
- 2026-07-15Phase 3 first posted: Merck Sharp & Dohme LLC, MK-8748 + Aflibercept (NCT07705555)
- 2026-07-15Phase 3 first posted: Merck Sharp & Dohme LLC, MK-8748 + Aflibercept (NCT07705607)
- 2026-07-10Phase 3 first posted: SANGMYUNG innovation, SMZ1 + SMZ1 Placebo (NCT07695207)
- 2026-06-30Results posted on the registry: Outlook Therapeutics, Inc., bevacizumab + ranibizumab (NCT06190093)
- 2026-05-29Phase 3 first posted: Amgen, ABP 938 8 mg + Aflibercept (US) 8 mg (NCT07614776)
- 2026-05-28Results posted on the registry: Regeneron Pharmaceuticals, aflibercept 8 mg PFS (NCT05989126)
- 2026-05-26Results posted on the registry: Laboratorios Sophia S.A de C.V., Bevacizumab + Lucentis® (NCT05217680)
- 2026-05-11Results posted on the registry: Hoffmann-La Roche, Vamikibart + Ranibizumab (NCT05151731)
- 2026-04-09Phase 3 first posted: Shenzhen Oculgen Biomedical Technology Co., Ltd., bispecific anti-VEGF and anti-complement (NCT07520318)
- 2026-04-07Phase 3 first posted: Bio-Thera Solutions, BAT5906 injection + Lucentis (NCT07515079)
- 2026-03-27Phase 3 first posted: EyeBiotech Ltd., Tiespectus + Aflibercept (NCT07496567)
- 2026-03-24Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QL1207H injection + Aflibercept 8 mg (NCT07489586)
- 2026-03-23Phase 3 first posted: Alvotech Swiss AG, AVT29 (proposed aflibercept HD biosimilar) + Eylea HD (aflibercept HD) (NCT07489131)
- 2026-03-19Phase 3 first posted: Adverum Biotechnologies, Inc., Ixo-vec + Aflibercept (NCT07482176)
- 2026-03-10Phase 3 first posted: Yeungnam University College of Medicine, Faricimab Injection [Vabysmo] (NCT07461441)
- 2026-03-04Phase 3 first posted: EyePoint Pharmaceuticals, Inc., EYP-1901 + Aflibercept (2.0 mg) (NCT07449936)
- 2026-03-04Phase 3 first posted: EyePoint Pharmaceuticals, Inc., EYP-1901 + Aflibercept (2.0 mg) (NCT07449923)
- 2026-02-27Phase 3 first posted: EyeBiotech Ltd., Tiespectus + Aflibercept (NCT07440225)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision